Australian company Starpharma (ASX:SPL) has announced it will present positive interim data from the trial of its DEP irinotecan at a key international oncology conference in October in the US.
Investors boost Starpharma in response to interim data from clinical trial
September 13, 2023 Australian BiotechLatest Video
New Stories
-
Cabinet documents reveal decades-old focus on faster PBS listings
January 24, 2025 - - Latest News -
No probity advisor but what about a form of confidentiality deed?
January 24, 2025 - - Latest News -
CEPI backing for Vaxxas to advance needle-free thermostable mRNA vaccines
January 23, 2025 - - Latest News -
New preventive treatments could support ongoing fight against COVID
January 23, 2025 - - Latest News -
Pharmac encourages input on on multiple medicines funding proposal
January 22, 2025 - - Latest News -
Immutep completes patient enrolment for EFTISARC-NEO Phase 2 trial
January 22, 2025 - - Australian Biotech -
Emyria announces key leadership changes
January 22, 2025 - - Latest News